0

Close
 
Upcoming Allied Market Research
2023
Heart Failure Diagnostics/therapeutics Market

Heart Failure Diagnostics/Therapeutics Market

by Therapy (Cardiac Resynchronization Therapy, Ventricular Assist Devices, Counterpulsation Implants, Heart Failure Surgery, Fluid Reduction (Renal Impairment), Neurostimulation, Hemodynamic Monitoring, Central Sleep Apnea), by Product (ECG Systems, Holter Monitors, Event Monitors, Implantable Loop Recorders) and by Tests (Blood Tests, Chest X Ray, Electrocardiogram, Echocardiogram, Stress Test, Cardiac Computerized Tomography (CT) Scan or Magnetic Resonance Imaging, Coronary Angiogram, Myocardial Biopsy): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Medical Devices & Supplies
Report Code: A03782
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Heart Failure Diagnostics/therapeutics Market

Request Now !

Heart failure or congestive heart failure is a phenomenon, which occurs when the heart muscle is not able to pump blood properly or when it leads to conditions such as high blood pressure, high cholesterol level, narrowing of blood vessels, and others. Heart failure diagnosis can be done by various ways such as blood tests, electrocardiogram chest x-ray, echocardiogram, and others.

Growth in incidence of heart failure, rise in incidence of diabetes, atherosclerosis, stroke, hypertension, and other conditions, technological advancements in cardiac heart failure treatment devices, sedentary lifestyle habits, and growth in geriatric population drive the market growth. However, reimbursement issues and high cost of diagnosing devices in the emerging countries are some of the factors that restrict the market growth. Moreover, new emerging technologies of cardiovascular treatment & diagnostics generate numerous opportunities in untapped markets in the near future.

The market is segmented on the basis of therapy, product, tests, and region. On the basis of therapy, it is divided into cardiac resynchronization therapy, ventricular assist devices, counterpulsation implants, heart failure surgery, fluid reduction, neurostimulation, hemodynamic monitoring, and central sleep apnea. On the basis of product, it is classified into electrocardiogram systems, holter monitors, event monitors, and implantable loop recorders.

On the basis of tests, it is categorized into electrocardiogram, blood tests, troponin, CK-MB, and others. By geography, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, UK, France, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

The key players profiled include Abbott Laboratories, Beckman Coulter, Abiomed Inc., Berlin Heart GmbH, Biotronik SE & Co. KG, Boston Scientific Corporation, HeartWare International Inc., Jarvik Heart Inc., Medtronic plc, and St. Jude Medical.

Key Benefits

  • The study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
  • Extensive analysis by product helps understand various types of therapies used for heart failure diagnostics.
  • Comprehensive analysis of all geographical regions is provided, which helps determine the prevailing opportunities.
  • Key players are profiled and their strategies are analyzed thoroughly, which elucidates the competitive outlook of the global market

 Heart Failure Diagnostics/Therapeutics Market Report Highlights

Aspects Details
By Therapy
  • Cardiac Resynchronization Therapy
  • Ventricular Assist Devices
  • Counterpulsation Implants
  • Heart Failure Surgery
  • Fluid Reduction (Renal Impairment)
  • Neurostimulation
  • Hemodynamic Monitoring
  • Central Sleep Apnea
By Product
  • ECG Systems
  • Holter Monitors
  • Event Monitors
  • Implantable Loop Recorders
By Tests
  • Blood Tests
  • Chest X Ray
  • Electrocardiogram
  • Echocardiogram
  • Stress Test
  • Cardiac Computerized Tomography (CT) Scan or Magnetic Resonance Imaging
  • Coronary Angiogram
  • Myocardial Biopsy
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players St. Jude Medical., Abiomed Inc., Abbott Laboratories, Medtronic plc, Beckman Coulter, Berlin Heart GmbH, Jarvik Heart Inc., Biotronik SE and Co. KG, Boston Scientific Corporation, HeartWare International Inc.
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET, BY THERAPY

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Therapy

    • 4.2. Cardiac Resynchronization Therapy

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Ventricular Assist Devices

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Counterpulsation Implants

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Heart Failure Surgery

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Fluid Reduction (Renal Impairment)

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

    • 4.7. Neurostimulation

      • 4.7.1. Key Market Trends, Growth Factors and Opportunities

      • 4.7.2. Market Size and Forecast, By Region

      • 4.7.3. Market Share Analysis, By Country

    • 4.8. Hemodynamic Monitoring

      • 4.8.1. Key Market Trends, Growth Factors and Opportunities

      • 4.8.2. Market Size and Forecast, By Region

      • 4.8.3. Market Share Analysis, By Country

    • 4.9. Central Sleep Apnea

      • 4.9.1. Key Market Trends, Growth Factors and Opportunities

      • 4.9.2. Market Size and Forecast, By Region

      • 4.9.3. Market Share Analysis, By Country

  • CHAPTER 5: HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET, BY PRODUCT

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Product

    • 5.2. ECG Systems

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Holter Monitors

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Event Monitors

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Implantable Loop Recorders

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

  • CHAPTER 6: HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET, BY TESTS

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Tests

    • 6.2. Blood Tests

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Chest X Ray

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Electrocardiogram

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Echocardiogram

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

    • 6.6. Stress Test

      • 6.6.1. Key Market Trends, Growth Factors and Opportunities

      • 6.6.2. Market Size and Forecast, By Region

      • 6.6.3. Market Share Analysis, By Country

    • 6.7. Cardiac Computerized Tomography (CT) Scan Or Magnetic Resonance Imaging

      • 6.7.1. Key Market Trends, Growth Factors and Opportunities

      • 6.7.2. Market Size and Forecast, By Region

      • 6.7.3. Market Share Analysis, By Country

    • 6.8. Coronary Angiogram

      • 6.8.1. Key Market Trends, Growth Factors and Opportunities

      • 6.8.2. Market Size and Forecast, By Region

      • 6.8.3. Market Share Analysis, By Country

    • 6.9. Myocardial Biopsy

      • 6.9.1. Key Market Trends, Growth Factors and Opportunities

      • 6.9.2. Market Size and Forecast, By Region

      • 6.9.3. Market Share Analysis, By Country

  • CHAPTER 7: HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Therapy

      • 7.2.3. Market Size and Forecast, By Product

      • 7.2.4. Market Size and Forecast, By Tests

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Heart Failure Diagnostics/therapeutics Market

        • 7.2.6.1. Market Size and Forecast, By Therapy
        • 7.2.6.2. Market Size and Forecast, By Product
        • 7.2.6.3. Market Size and Forecast, By Tests

      • 7.2.7. Canada Heart Failure Diagnostics/therapeutics Market

        • 7.2.7.1. Market Size and Forecast, By Therapy
        • 7.2.7.2. Market Size and Forecast, By Product
        • 7.2.7.3. Market Size and Forecast, By Tests

      • 7.2.8. Mexico Heart Failure Diagnostics/therapeutics Market

        • 7.2.8.1. Market Size and Forecast, By Therapy
        • 7.2.8.2. Market Size and Forecast, By Product
        • 7.2.8.3. Market Size and Forecast, By Tests

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Therapy

      • 7.3.3. Market Size and Forecast, By Product

      • 7.3.4. Market Size and Forecast, By Tests

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Heart Failure Diagnostics/therapeutics Market

        • 7.3.6.1. Market Size and Forecast, By Therapy
        • 7.3.6.2. Market Size and Forecast, By Product
        • 7.3.6.3. Market Size and Forecast, By Tests

      • 7.3.7. Germany Heart Failure Diagnostics/therapeutics Market

        • 7.3.7.1. Market Size and Forecast, By Therapy
        • 7.3.7.2. Market Size and Forecast, By Product
        • 7.3.7.3. Market Size and Forecast, By Tests

      • 7.3.8. Italy Heart Failure Diagnostics/therapeutics Market

        • 7.3.8.1. Market Size and Forecast, By Therapy
        • 7.3.8.2. Market Size and Forecast, By Product
        • 7.3.8.3. Market Size and Forecast, By Tests

      • 7.3.9. Spain Heart Failure Diagnostics/therapeutics Market

        • 7.3.9.1. Market Size and Forecast, By Therapy
        • 7.3.9.2. Market Size and Forecast, By Product
        • 7.3.9.3. Market Size and Forecast, By Tests

      • 7.3.10. UK Heart Failure Diagnostics/therapeutics Market

        • 7.3.10.1. Market Size and Forecast, By Therapy
        • 7.3.10.2. Market Size and Forecast, By Product
        • 7.3.10.3. Market Size and Forecast, By Tests

      • 7.3.11. Russia Heart Failure Diagnostics/therapeutics Market

        • 7.3.11.1. Market Size and Forecast, By Therapy
        • 7.3.11.2. Market Size and Forecast, By Product
        • 7.3.11.3. Market Size and Forecast, By Tests

      • 7.3.12. Rest Of Europe Heart Failure Diagnostics/therapeutics Market

        • 7.3.12.1. Market Size and Forecast, By Therapy
        • 7.3.12.2. Market Size and Forecast, By Product
        • 7.3.12.3. Market Size and Forecast, By Tests

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Therapy

      • 7.4.3. Market Size and Forecast, By Product

      • 7.4.4. Market Size and Forecast, By Tests

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Heart Failure Diagnostics/therapeutics Market

        • 7.4.6.1. Market Size and Forecast, By Therapy
        • 7.4.6.2. Market Size and Forecast, By Product
        • 7.4.6.3. Market Size and Forecast, By Tests

      • 7.4.7. Japan Heart Failure Diagnostics/therapeutics Market

        • 7.4.7.1. Market Size and Forecast, By Therapy
        • 7.4.7.2. Market Size and Forecast, By Product
        • 7.4.7.3. Market Size and Forecast, By Tests

      • 7.4.8. India Heart Failure Diagnostics/therapeutics Market

        • 7.4.8.1. Market Size and Forecast, By Therapy
        • 7.4.8.2. Market Size and Forecast, By Product
        • 7.4.8.3. Market Size and Forecast, By Tests

      • 7.4.9. South Korea Heart Failure Diagnostics/therapeutics Market

        • 7.4.9.1. Market Size and Forecast, By Therapy
        • 7.4.9.2. Market Size and Forecast, By Product
        • 7.4.9.3. Market Size and Forecast, By Tests

      • 7.4.10. Australia Heart Failure Diagnostics/therapeutics Market

        • 7.4.10.1. Market Size and Forecast, By Therapy
        • 7.4.10.2. Market Size and Forecast, By Product
        • 7.4.10.3. Market Size and Forecast, By Tests

      • 7.4.11. Thailand Heart Failure Diagnostics/therapeutics Market

        • 7.4.11.1. Market Size and Forecast, By Therapy
        • 7.4.11.2. Market Size and Forecast, By Product
        • 7.4.11.3. Market Size and Forecast, By Tests

      • 7.4.12. Malaysia Heart Failure Diagnostics/therapeutics Market

        • 7.4.12.1. Market Size and Forecast, By Therapy
        • 7.4.12.2. Market Size and Forecast, By Product
        • 7.4.12.3. Market Size and Forecast, By Tests

      • 7.4.13. Indonesia Heart Failure Diagnostics/therapeutics Market

        • 7.4.13.1. Market Size and Forecast, By Therapy
        • 7.4.13.2. Market Size and Forecast, By Product
        • 7.4.13.3. Market Size and Forecast, By Tests

      • 7.4.14. Rest of Asia Pacific Heart Failure Diagnostics/therapeutics Market

        • 7.4.14.1. Market Size and Forecast, By Therapy
        • 7.4.14.2. Market Size and Forecast, By Product
        • 7.4.14.3. Market Size and Forecast, By Tests

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Therapy

      • 7.5.3. Market Size and Forecast, By Product

      • 7.5.4. Market Size and Forecast, By Tests

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Heart Failure Diagnostics/therapeutics Market

        • 7.5.6.1. Market Size and Forecast, By Therapy
        • 7.5.6.2. Market Size and Forecast, By Product
        • 7.5.6.3. Market Size and Forecast, By Tests

      • 7.5.7. South Africa Heart Failure Diagnostics/therapeutics Market

        • 7.5.7.1. Market Size and Forecast, By Therapy
        • 7.5.7.2. Market Size and Forecast, By Product
        • 7.5.7.3. Market Size and Forecast, By Tests

      • 7.5.8. Saudi Arabia Heart Failure Diagnostics/therapeutics Market

        • 7.5.8.1. Market Size and Forecast, By Therapy
        • 7.5.8.2. Market Size and Forecast, By Product
        • 7.5.8.3. Market Size and Forecast, By Tests

      • 7.5.9. UAE Heart Failure Diagnostics/therapeutics Market

        • 7.5.9.1. Market Size and Forecast, By Therapy
        • 7.5.9.2. Market Size and Forecast, By Product
        • 7.5.9.3. Market Size and Forecast, By Tests

      • 7.5.10. Argentina Heart Failure Diagnostics/therapeutics Market

        • 7.5.10.1. Market Size and Forecast, By Therapy
        • 7.5.10.2. Market Size and Forecast, By Product
        • 7.5.10.3. Market Size and Forecast, By Tests

      • 7.5.11. Rest of LAMEA Heart Failure Diagnostics/therapeutics Market

        • 7.5.11.1. Market Size and Forecast, By Therapy
        • 7.5.11.2. Market Size and Forecast, By Product
        • 7.5.11.3. Market Size and Forecast, By Tests

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning,2022

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Abbott Laboratories

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Beckman Coulter

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Abiomed Inc.

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Berlin Heart GmbH

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Biotronik SE And Co. KG

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Boston Scientific Corporation

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. HeartWare International Inc.

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Jarvik Heart Inc.

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Medtronic Plc

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. St. Jude Medical.

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET FOR CARDIAC RESYNCHRONIZATION THERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET FOR VENTRICULAR ASSIST DEVICES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET FOR COUNTERPULSATION IMPLANTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET FOR HEART FAILURE SURGERY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET FOR FLUID REDUCTION (RENAL IMPAIRMENT), BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET FOR NEUROSTIMULATION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET FOR HEMODYNAMIC MONITORING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET FOR CENTRAL SLEEP APNEA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET FOR ECG SYSTEMS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET FOR HOLTER MONITORS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET FOR EVENT MONITORS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET FOR IMPLANTABLE LOOP RECORDERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET, BY TESTS, 2022-2032 ($MILLION)
  • TABLE 16. GLOBAL HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET FOR BLOOD TESTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. GLOBAL HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET FOR CHEST X RAY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. GLOBAL HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET FOR ELECTROCARDIOGRAM, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. GLOBAL HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET FOR ECHOCARDIOGRAM, BY REGION, 2022-2032 ($MILLION)
  • TABLE 20. GLOBAL HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET FOR STRESS TEST, BY REGION, 2022-2032 ($MILLION)
  • TABLE 21. GLOBAL HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET FOR CARDIAC COMPUTERIZED TOMOGRAPHY (CT) SCAN OR MAGNETIC RESONANCE IMAGING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 22. GLOBAL HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET FOR CORONARY ANGIOGRAM, BY REGION, 2022-2032 ($MILLION)
  • TABLE 23. GLOBAL HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET FOR MYOCARDIAL BIOPSY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 24. GLOBAL HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 25. NORTH AMERICA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 26. NORTH AMERICA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 27. NORTH AMERICA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 28. NORTH AMERICA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY TESTS, 2022-2032 ($MILLION)
  • TABLE 29. U.S. HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 30. U.S. HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 31. U.S. HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY TESTS, 2022-2032 ($MILLION)
  • TABLE 32. CANADA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 33. CANADA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 34. CANADA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY TESTS, 2022-2032 ($MILLION)
  • TABLE 35. MEXICO HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 36. MEXICO HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 37. MEXICO HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY TESTS, 2022-2032 ($MILLION)
  • TABLE 38. EUROPE HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 39. EUROPE HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 40. EUROPE HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 41. EUROPE HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY TESTS, 2022-2032 ($MILLION)
  • TABLE 42. FRANCE HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 43. FRANCE HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 44. FRANCE HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY TESTS, 2022-2032 ($MILLION)
  • TABLE 45. GERMANY HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 46. GERMANY HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 47. GERMANY HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY TESTS, 2022-2032 ($MILLION)
  • TABLE 48. ITALY HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 49. ITALY HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 50. ITALY HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY TESTS, 2022-2032 ($MILLION)
  • TABLE 51. SPAIN HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 52. SPAIN HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 53. SPAIN HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY TESTS, 2022-2032 ($MILLION)
  • TABLE 54. UK HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 55. UK HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 56. UK HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY TESTS, 2022-2032 ($MILLION)
  • TABLE 57. RUSSIA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 58. RUSSIA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 59. RUSSIA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY TESTS, 2022-2032 ($MILLION)
  • TABLE 60. REST OF EUROPE HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 61. REST OF EUROPE HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 62. REST OF EUROPE HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY TESTS, 2022-2032 ($MILLION)
  • TABLE 63. ASIA-PACIFIC HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 64. ASIA-PACIFIC HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 65. ASIA-PACIFIC HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 66. ASIA-PACIFIC HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY TESTS, 2022-2032 ($MILLION)
  • TABLE 67. CHINA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 68. CHINA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 69. CHINA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY TESTS, 2022-2032 ($MILLION)
  • TABLE 70. JAPAN HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 71. JAPAN HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 72. JAPAN HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY TESTS, 2022-2032 ($MILLION)
  • TABLE 73. INDIA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 74. INDIA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 75. INDIA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY TESTS, 2022-2032 ($MILLION)
  • TABLE 76. SOUTH KOREA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 77. SOUTH KOREA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 78. SOUTH KOREA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY TESTS, 2022-2032 ($MILLION)
  • TABLE 79. AUSTRALIA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 80. AUSTRALIA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 81. AUSTRALIA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY TESTS, 2022-2032 ($MILLION)
  • TABLE 82. THAILAND HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 83. THAILAND HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 84. THAILAND HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY TESTS, 2022-2032 ($MILLION)
  • TABLE 85. MALAYSIA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 86. MALAYSIA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 87. MALAYSIA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY TESTS, 2022-2032 ($MILLION)
  • TABLE 88. INDONESIA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 89. INDONESIA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 90. INDONESIA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY TESTS, 2022-2032 ($MILLION)
  • TABLE 91. REST OF ASIA PACIFIC HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 92. REST OF ASIA PACIFIC HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 93. REST OF ASIA PACIFIC HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY TESTS, 2022-2032 ($MILLION)
  • TABLE 94. LAMEA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 95. LAMEA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 96. LAMEA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 97. LAMEA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY TESTS, 2022-2032 ($MILLION)
  • TABLE 98. BRAZIL HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 99. BRAZIL HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 100. BRAZIL HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY TESTS, 2022-2032 ($MILLION)
  • TABLE 101. SOUTH AFRICA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 102. SOUTH AFRICA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 103. SOUTH AFRICA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY TESTS, 2022-2032 ($MILLION)
  • TABLE 104. SAUDI ARABIA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 105. SAUDI ARABIA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 106. SAUDI ARABIA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY TESTS, 2022-2032 ($MILLION)
  • TABLE 107. UAE HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 108. UAE HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 109. UAE HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY TESTS, 2022-2032 ($MILLION)
  • TABLE 110. ARGENTINA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 111. ARGENTINA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 112. ARGENTINA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY TESTS, 2022-2032 ($MILLION)
  • TABLE 113. REST OF LAMEA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 114. REST OF LAMEA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 115. REST OF LAMEA HEART FAILURE DIAGNOSTICS/THERAPEUTICS, BY TESTS, 2022-2032 ($MILLION)
  • TABLE 116. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 117. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 118. ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 119. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 120. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 121. BECKMAN COULTER: KEY EXECUTIVES
  • TABLE 122. BECKMAN COULTER: COMPANY SNAPSHOT
  • TABLE 123. BECKMAN COULTER: OPERATING SEGMENTS
  • TABLE 124. BECKMAN COULTER: PRODUCT PORTFOLIO
  • TABLE 125. BECKMAN COULTER: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 126. ABIOMED INC.: KEY EXECUTIVES
  • TABLE 127. ABIOMED INC.: COMPANY SNAPSHOT
  • TABLE 128. ABIOMED INC.: OPERATING SEGMENTS
  • TABLE 129. ABIOMED INC.: PRODUCT PORTFOLIO
  • TABLE 130. ABIOMED INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 131. BERLIN HEART GMBH: KEY EXECUTIVES
  • TABLE 132. BERLIN HEART GMBH: COMPANY SNAPSHOT
  • TABLE 133. BERLIN HEART GMBH: OPERATING SEGMENTS
  • TABLE 134. BERLIN HEART GMBH: PRODUCT PORTFOLIO
  • TABLE 135. BERLIN HEART GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 136. BIOTRONIK SE AND CO. KG: KEY EXECUTIVES
  • TABLE 137. BIOTRONIK SE AND CO. KG: COMPANY SNAPSHOT
  • TABLE 138. BIOTRONIK SE AND CO. KG: OPERATING SEGMENTS
  • TABLE 139. BIOTRONIK SE AND CO. KG: PRODUCT PORTFOLIO
  • TABLE 140. BIOTRONIK SE AND CO. KG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 141. BOSTON SCIENTIFIC CORPORATION: KEY EXECUTIVES
  • TABLE 142. BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
  • TABLE 143. BOSTON SCIENTIFIC CORPORATION: OPERATING SEGMENTS
  • TABLE 144. BOSTON SCIENTIFIC CORPORATION: PRODUCT PORTFOLIO
  • TABLE 145. BOSTON SCIENTIFIC CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 146. HEARTWARE INTERNATIONAL INC.: KEY EXECUTIVES
  • TABLE 147. HEARTWARE INTERNATIONAL INC.: COMPANY SNAPSHOT
  • TABLE 148. HEARTWARE INTERNATIONAL INC.: OPERATING SEGMENTS
  • TABLE 149. HEARTWARE INTERNATIONAL INC.: PRODUCT PORTFOLIO
  • TABLE 150. HEARTWARE INTERNATIONAL INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 151. JARVIK HEART INC.: KEY EXECUTIVES
  • TABLE 152. JARVIK HEART INC.: COMPANY SNAPSHOT
  • TABLE 153. JARVIK HEART INC.: OPERATING SEGMENTS
  • TABLE 154. JARVIK HEART INC.: PRODUCT PORTFOLIO
  • TABLE 155. JARVIK HEART INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 156. MEDTRONIC PLC: KEY EXECUTIVES
  • TABLE 157. MEDTRONIC PLC: COMPANY SNAPSHOT
  • TABLE 158. MEDTRONIC PLC: OPERATING SEGMENTS
  • TABLE 159. MEDTRONIC PLC: PRODUCT PORTFOLIO
  • TABLE 160. MEDTRONIC PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 161. ST. JUDE MEDICAL.: KEY EXECUTIVES
  • TABLE 162. ST. JUDE MEDICAL.: COMPANY SNAPSHOT
  • TABLE 163. ST. JUDE MEDICAL.: OPERATING SEGMENTS
  • TABLE 164. ST. JUDE MEDICAL.: PRODUCT PORTFOLIO
  • TABLE 165. ST. JUDE MEDICAL.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET
  • FIGURE 3. SEGMENTATION HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALHEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET
  • FIGURE 11. HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET SEGMENTATION, BY BY THERAPY
  • FIGURE 12. HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET FOR CARDIAC RESYNCHRONIZATION THERAPY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET FOR VENTRICULAR ASSIST DEVICES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET FOR COUNTERPULSATION IMPLANTS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET FOR HEART FAILURE SURGERY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET FOR FLUID REDUCTION (RENAL IMPAIRMENT), BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET FOR NEUROSTIMULATION, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET FOR HEMODYNAMIC MONITORING, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET FOR CENTRAL SLEEP APNEA, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET SEGMENTATION, BY BY PRODUCT
  • FIGURE 21. HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET FOR ECG SYSTEMS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET FOR HOLTER MONITORS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET FOR EVENT MONITORS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 24. HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET FOR IMPLANTABLE LOOP RECORDERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 25. HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET SEGMENTATION, BY BY TESTS
  • FIGURE 26. HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET FOR BLOOD TESTS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 27. HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET FOR CHEST X RAY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 28. HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET FOR ELECTROCARDIOGRAM, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 29. HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET FOR ECHOCARDIOGRAM, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 30. HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET FOR STRESS TEST, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 31. HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET FOR CARDIAC COMPUTERIZED TOMOGRAPHY (CT) SCAN OR MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 32. HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET FOR CORONARY ANGIOGRAM, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 33. HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET FOR MYOCARDIAL BIOPSY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 34. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 35. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 36. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 37. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 38. COMPETITIVE DASHBOARD
  • FIGURE 39. COMPETITIVE HEATMAP: HEART FAILURE DIAGNOSTICS/THERAPEUTICS MARKET
  • FIGURE 40. Top player positioning, 2022
  • FIGURE 41. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 42. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 43. ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 44. BECKMAN COULTER: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 45. BECKMAN COULTER: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 46. BECKMAN COULTER: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 47. ABIOMED INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 48. ABIOMED INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 49. ABIOMED INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 50. BERLIN HEART GMBH: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 51. BERLIN HEART GMBH: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 52. BERLIN HEART GMBH: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 53. BIOTRONIK SE AND CO. KG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 54. BIOTRONIK SE AND CO. KG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 55. BIOTRONIK SE AND CO. KG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 56. BOSTON SCIENTIFIC CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 57. BOSTON SCIENTIFIC CORPORATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 58. BOSTON SCIENTIFIC CORPORATION: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 59. HEARTWARE INTERNATIONAL INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 60. HEARTWARE INTERNATIONAL INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 61. HEARTWARE INTERNATIONAL INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 62. JARVIK HEART INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 63. JARVIK HEART INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 64. JARVIK HEART INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 65. MEDTRONIC PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 66. MEDTRONIC PLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 67. MEDTRONIC PLC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 68. ST. JUDE MEDICAL.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 69. ST. JUDE MEDICAL.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 70. ST. JUDE MEDICAL.: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Heart Failure Diagnostics/therapeutics Market

Start reading.
This Report and over 66,944+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers